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ABSTRACT
Objective: A simple and fast analytical method of ultra-high performance liquid chromatography (UHPLC) was developed and validated to quantify 
isradipine (ISR) in poly(ε-caprolactone)/polyethylene glycol nanocapsules.
Methods: Experiments were performed by UHPLC on a C18 chromatographic column at 25°C, using a mobile phase composed by methanol and water 
(85:15 v/v) with a flow rate of 0.5 ml/min and UV detection at 327nm for achieving a total run time of 1.5 min. The UHPLC method was validated 
according to the guidelines set on The International Conference on Harmonisation.
Results: It proved to be selective, linear (r=0.99962), precise (relative standard deviation <4.1%), and accurate (recovery rates between 95.24% and 
96.53%) at the range from 10 to 40 µg/ml. The performance was robust when slight changes in the flow rate, wavelength of detection, and mobile 
phase composition were tested. It was successfully applied to quantify ISR from nanoparticulate polymeric systems, showing a high loading efficiency 
rate, >98.55%.
Conclusion: These results provided an experimental basis to use this method for quantifying ISR with reliable results, besides being fast, easy to 
perform, and cheaper.
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INTRODUCTION
Quality control has been an essential tool for pharmaceutical 
industries since it ensures efficacy and safety for pharmaceutical 
products. Nevertheless, its results are only reliable when analytical 
methods employed are validated [1]. The validation of an analytical 
method is a major approach for assuring its quality, especially when 
the need to prove the quality of pharmaceutical analysis has been 
increasingly recognized and demanded since unreliable data can 
lead to wrong decisions and irrecoverable financial losses [2]. In 
this sense, ultra-high performance liquid chromatography (UHPLC) 
brought new opportunities in pharmaceutical industries to get faster 
analytical separation results while remaining the method quality. Its 
technique speed results in reduced consumption of solvent while 
presents a resolution and sensitivity greater than other conventional 
techniques [3].
The isradipine (ISR) or 3-methyl 5-propan-2-yl 4-(2,1,3-benzoxadiazol-
4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate is a calcium 
channel blocker which belongs to the dihydropyridine class and has 
demonstrated an interesting neuroprotective effect associated to its 
pharmacotherapeutic use [4]. In this case, the main challenge is to get 
this drug to cross the blood-brain barrier in therapeutic concentrations. 
The clinical study performed demonstrated that the dose of ISR as 
immediate-release formulation may have been insufficient to engage 
the target calcium channels associated with neuroprotective effects [5]. 
Thus, the research for strategies that make it possible to deflect the 
limitations related to the action of this drug in the central nervous 
system is growing and current.
In this context, polymeric nanocapsules have an interesting application 
for delivering drugs in the central nervous system, accompanied 
by its controlled release at the site [6,7]. Before the advantages 
offered by nanoparticulate systems, there is a demand for a reliable 
method capable of quantifying the drug in these formulations. Some 
chromatographic methods to quantify ISR have been previously 
reported in the literature [8-12]. However, none of them is appropriate 
to quantify drug-loaded polymeric nanocapsules, besides presenting 
complexes steps and wasting more expensive products. Hence, the aim 
of this paper was to develop and validate a reversed-phase UHPLC-
photodiode array (RP-UHPLC-PDA) method to quantify ISR loaded in 
poly(ε-caprolactone) (PCL)/polyethylene glycol (PEG) nanocapsules.
METHODS
ISR hydrochloride (European Pharmacopoeia reference standard, CAS 
number 75695-93-1), PCL (Mw = 10 000 g/mol, Sigma-Aldrich, St. Louis, 
MO, USA), and PEG (Mw = 6000 g/mol, Fluka, St. Louis, MO, USA) were 
used as received. Methanol of gradient grade for liquid chromatography 
was purchased from Merck (Darmstadt, Germany). All other chemicals 
used were of analytical grade.
Preparation of polymeric nanocapsules containing ISR
Nanocapsule suspensions obtained from PCL/PEG polymer blend 
(80:20) containing isradipine (NC-ISR) were prepared in triplicate by 
the interfacial deposition procedure of a preformed polymer developed 
and described by Fessi et al. [13], according to the formulation 
described in Table 1. Besides the loaded formulation, nanocapsules 
without the drug were also produced in triplicate as a negative control 
(NC-0). Briefly, the polymer blend was solvated in acetone, along with 
sorbitan monooleate, ISR, and caprylic/capric triglycerides to obtain 
the organic phase. Then, the organic phase was dripped slowly into 
the aqueous phase, previously prepared with ultrapure water and 
polysorbate 80, and maintained under vigorous magnetic stirring and 
© 2020 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2020.v13i8.38817
Research Article
temperature between 40°C and 50°C. In addition, the magnetic stirring 
was maintained for 10 min after the end of the drip and the solvent 
was eliminated by rotary evaporation at 50°C, reaching a final volume 
of 10 ml and a drug concentration of 2 mg/ml.
In sequence, the resulting nanosuspension was added with 5% of 
sucrose (w/v), as a cryoprotective agent, frozen at –80°C for 24 h, and 
lyophilized in a Terroni® lyophilizer model LD1500 for 48 h. To modify 
the surface of the nanocapsules [14], they were coated with polysorbate 
80 after completing the conventional process for obtaining the 
nanoparticulate system. For this, the powder resulting from the freeze-
drying was resuspended in 2 ml of a solution of polysorbate 80 (1%, 
w/v). The suspension remained incubated at room temperature for 
30 min, was frozen again at −80°C for 24 h, and freeze-dried for 72 h. 
The final powder was stored in a desiccator at room temperature and 
protected from light.
Chromatographic conditions
Chromatographic conditions were tested and defined by the authors. 
Different composition, pH, and flow rate of the mobile phase were 
tested, as well as column temperature and detection wavelength.
Experiments were performed in a Shimadzu Nexera System® UHPLC, 
equipped with a quaternary pump (LC-30AD), degasser (DGU-20A), 
automatic sampler (SIL-30 AC), thermostatic column compartment 
(CTO-20AC), and a photodiode array detector (SPD-M20A). The 
analytical column used was a Shimadzu Shim-pack XR-ODS III (C18; 
2.0 mm internal diameter × 75 mm long; particle size of 1.6 µm). The 
isocratic mobile phase consisted of methanol:water (85:15 v/v) with a 
flow rate of 0.5 ml/min; temperature of 25°C, injection volume of 10 µl, 
and wavelength detection at 327 nm. The total analytical run time was 
1.5 min. The acquisition and processing of the data were obtained with 
the LabSolutions® Software (Shimadzu, Japan).
Preparation of standard solutions
A stock standard solution of 1 mg/ml of ISR was daily prepared by 
dissolving 10 mg of the drug in a 10 ml volumetric flask with methanol. 
This solution was further diluted in the mobile phase to prepare 
five different standard solutions ranging from 10 to 40 µg/ml. Final 
solutions were filtered through a poly(vinylidene fluoride) membrane 
filter (Durapore® membrane filter, 0.22 µm pore size) before injection 
into the UHPLC system.
Preparation of sample solutions
The final dosage form, a nanopowder, was resuspended in 10 ml 
of purified water. The nanosuspension (500 µl) was submitted to 
ultrafiltration in an Amicon® device (Mw cutoff = 10,000 g/mol, Merck 
Millipore) by centrifugation at 2200 rcf for 30 min. The amount of free 
ISR in ultrafiltration fraction was chromatographically quantified as 
proposed. All procedure was performed in triplicate.
Method validation
The UHPLC method was validated according to the guidelines set on The 
International Conference on Harmonization of Technical Requirements 
for Registration of Pharmaceuticals for Human Use [15]. Parameters 
evaluated were selectivity, linearity and range, limit of detection (LOD), 
limit of quantification (LOQ), precision, accuracy, and robustness.
Selectivity was investigated by comparing both chromatograms of the 
standard solution and the sample solution from NC-0, obtained from the 
ultrafiltration of the nanosuspension prepared without ISR. Both solutions 
were chromatographed under previously defined conditions. The linearity 
of the method was assessed by preparing and analyzing of three analytical 
curves. For this, five concentration levels of ISR were obtained from 
dilutions of the standard solution in the mobile phase. The range was 
defined based on the intensity of the peaks produced in the chromatogram, 
including an interval from 10.0 µg/ml to 40.0 µg/ml. The analysis of 
linear regression was performed using the least-squares method and the 
slope was tested by ANOVA at a significance level of 0.05. LOD and LOQ 
were obtained based on the standard deviation of the response (s) and 
the slope (a) of three analytical curves (LOD = 3.3 s/a and LOQ = 10 s/a). 
Repeatability and intermediate precision were carried out by assaying six 
different samples at the same concentration (25.0 µg/ml) under the same 
experimental conditions during the same day (morning, afternoon, and 
night) and along three different days with different analysts, respectively. 
These results were expressed as relative standard deviation (RSD). 
Accuracy was determined by the recovery test. Different standard solutions 
were prepared and added to a known quantity of ISR. Final solutions were 
analyzed in the chromatographic system in triplicate. Robustness of the 
method was assessed from variations of the recommended conditions 
(mobile phase composition, flow rate, and wavelength of drug detection).
Method applicability: Determination of ISR loading efficiency
The amount of ISR was calculated and reported as loading efficiency 
following the equation below. Loading efficiency (%) was determined 
from the sample solution. Non-entrapped ISR was quantified in the 
ultrafiltrate by the proposed chromatographic method.





Preparation of polymeric nanocapsules containing ISR
Nanocapsules from PCL/PEG polymer blend were successfully obtained 
by the proposed method. Formulations showed a powder aspect with a 
slightly yellowish-white coloring.
Method validation
The main parameters related to the proposed method for quantification 
of ISR are briefly described in Table 2.
The UHPLC method presented a total run time of 1.5 min and proved 
to be selective since the NC-0 formulation did not show relevant signal 
detection overlap at the same reading position of the drug (Fig. 1).
The linearity test was performed at five different concentrations level 
of the analyte and its mean analytical curve obtained is shown in Fig. 2.
Values of angular coefficient (slope of the line), linear coefficient 
(Y-intercept), Pearson’s correlation coefficient (r), and coefficient 
of determination (r2) were obtained based on the linear regression 
analysis and were able to evidence the quality of the linear regression 
obtained. Results are described in Table 3.
Results showed that the Pearson’s correlation coefficient statistically is 
equal to 1 and a non-zero slope (significance level of 0.05%).
To demonstrate that y really varies as a function of x, it has been shown 
that the variation due to the regression (model) is sufficiently greater 
Table 1: Formulations of the loaded and non-loaded nanocapsule suspensions
Formulation Organic phase Aqueous phase
ISR (mg) PCL (mg) PEG (mg) CCT (mg) Acetone (ml) Sorbitan monooleate (mg) Polysorbate 80 (mg) Water (ml)
NC-ISR 20 80 20 300 27 77 77 53
NC-0 - 80 20 300 27 77 77 53
NC-ISR: Nanocapsules containing isradipine, NC-0: Negative control, PCL: Poly(ε-caprolactone), PEG: Polyethylene glycol, CCT: Capric triglycerides
226
 Barboza et al.
Asian J Pharm Clin Res, Vol 13, Issue 8, 2020, 225-229
than that one due to the error (residuals). In this way, the residues were 
graphically plotted in Fig. 3.
The visual analysis indicated that the residues are independent and 
homogeneously distributed according to the mean.
The developed method showed a LOD of 2.9 µg/ml and a LOQ of 8.78 µg/ml.
The results of repeatability and intermediate precision obtained for this 
UHPLC-PDA method are shown in Table 4.
The obtained values of RSD were <5.0%.
Regarding accuracy, the recovery rate of ISR is between 95.24% and 
96.53% for different concentration levels evaluated. Table 5 describes 
the obtained data.
Recovery rates obtained for robustness are summarized in Table 6. 
These values showed a variation <5% due to small changes in the flow 
rate, wavelength of detection, and the organic phase concentration in 
the mobile phase.
Method applicability: Determination of ISR loading efficiency
Loading efficiency of ISR from nanocapsules was performed by the 
purposed RP-UHPLC-PDA method.
The chromatograms obtained from the ultrafiltrate samples showed 
no peaks; that is, there is no detectable concentration of free ISR in 
Table 2: Main parameters of the RP-UHPLC-PDA method for 
quantifying isradipine from polymeric nanocapsules
Parameters Results*
Retention time (min) 0.699±0.001
Width at 5% of the peak height (min) 0.208±0.001
Tailing factor 1.485±0.006
*Mean±standard deviation. RP-UHPLC-PDA: Reversed-phase-ultra-high 
performance liquid chromatography-photodiode array
Table 3: Linearity parameters of the RP-UHPLC-PDA method for 
quantifying isradipine from polymeric nanocapsules
Parameters Results
Linearity range 10–40 µg/ml
Linear equation (y = ax + b) y = 38 100x−8723.8
Slope (a) 38 100.0
Y-intercept (b) −8723.8
Pearson’s correlation coefficient (r) 0.99962
Coefficient of determination (r2) 0.99899
RP-UHPLC-PDA: Reversed-phase-ultra-high performance liquid 
chromatography-photodiode array
Table 4: Results of precision assays of the RP-UHPLC-PDA 
method for quantifying isradipine from polymeric nanocapsules
Parameters Sample concentration 
(µg/ml)
RSD* (%)
Repeatability (n=6) 25 4.02
Intermediate precision (n=12) 25 3.70
*RSD means relative standard deviation. RSD: Relative standard 
deviation, RP-UHPLC-PDA: Reversed-phase-ultra-high performance liquid 
chromatography-photodiode array
Table 5: Results of accuracy assays of the RP-UHPLC-PDA method 
for quantifying isradipine from polymeric nanocapsules
Theoretical sample concentration 
(µg/ml)





RP-UHPLC-PDA: Reversed-phase-ultra-high performance liquid 
chromatography-photodiode array
Fig. 1: Representative chromatogram of pure isradipine and NC-0 
formulation
Fig. 2: Graphical representation of the mean analytical curve 
obtained to quantify isradipine by RP-UHPLC-PDA method at a 
concentration range from 10 to 40 µg/ml
Fig. 3: Graphical representation of the residues obtained from 
replicates of each concentration level of the analytical curves
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the nanosuspension. Thus, it is possible to assert that the prepared 
polymeric system was able to incorporate ISR in its interior, with 
efficiency >98.55%, considering the value that meets to the LOD of the 
method.
DISCUSSION
Pharmaceutical quality control requires that its results are reliable and 
reproducible. For this, it is imperative to use methods that meet these 
demands besides being fast, easy to perform, and inexpensive. In this 
sense, the method developed in this work is very fast and simple and 
presents a lower cost when compared to the other methods that have 
already been described for quantification of ISR, whereas the mobile 
phase is composed only by methanol and ultra-purified water [8-12].
Analytically, we can say that the peak width at the base is adequate to 
guarantee the quality of the developed method, on the other hand, the 
peak tailing factor shows that it is not perfectly symmetrical since the 
ideal symmetry is represented by values equal to 1. However, Petersson 
et al. [16] describe that the UHPLC, which has columns with particle 
sizes smaller than 2 µm, produces tailing factor values significantly 
higher than the equivalent HPLC, which uses columns with 3 µm 
particles when the same amount of sample is injected. Expressions 
have shown that the tailing factor values change with the particle size 
and the number of theoretical plates, and even so, UHPLC produces 
more efficient separations when considered adjacent peaks. Thus, the 
tailing factor value must be analyzed, not singly, but rather associated 
with the peak width values at the base, to obtain a better parameter for 
measuring the quality of the method.
The validation process is responsible for ensuring that the results 
obtained are befitting. Moreover, once the parameters recommended 
by official agencies are strictly respected, the validation is able to prove 
that the analytical method employed produces reliable results, and it is 
suitable for the purpose for which it was intended [15,17].
The method developed for quantification of ISR proved to be 
selective since no excipient of the formulation showed absorption of 
electromagnetic radiation at the selected wavelength [18]. In this way, it 
ensures the ability of the method to quantify the drug before any other 
component. It generates an exclusive response to ISR allowing ensuring 
a positive result for the analyte and negative for the other substances.
The linearity test showed the method ability to get replies proportionally 
equivalent to the concentration of the drug within the stated range. It 
is known that the closer to 1 the Pearson’s correlation coefficient is, 
the smaller the dispersion among the points and the greater the safety 
of the results [19]. Thus, it is clear the relevance of using a calibration 
curve instead of a single point for standardization in the analysis 
routine. In addition, the visual analysis indicated that the residues are 
independent and homogeneously distributed according to the mean, 
ensuring the reliability of the reply generated by the method [20].
The LOD, which refers to the lowest concentration of the analyte that 
the method is able to detect, and the LOQ, which is the smallest amount 
of substance that the method is able to quantify with precision and 
accuracy, confirmed the feasibility of applying the method within the 
stated concentration range [21].
Official agencies describe that precision must be able to assess the 
closeness among the values found in the experiments and must be 
expressed as repeatability and intermediate precision [15]. In this work, 
repeatability showed the agreement among the results found when the 
method was performed under the same conditions, in a short time interval. 
When the intermediate precision was tested, the method performance 
showed a low variation when the analysis were accomplished in different 
days and with different analyzers, at the same laboratory [22].
The results also showed the agreement between the data obtained 
against the actual reference value when employing the quantification 
method of ISR, proving to be accurate [23].
In addition, the method was evaluated for the ability to withstand slight 
variations in the conditions of analysis, without hazarding its accuracy. 
In view of the recovery values obtained, the method was considered 
robust. Its robustness values the results obtained from this method 
enforcement since we assume that it can be reproduced without major 
problems [21].
When the UHPLC method was assayed to quantify the ISR 
nanoencapsulated in polymeric nanocapsules, it results in a high 
encapsulation rate. This rate its completely expected due to the high 
lipophilicity of the drug (water solubility <10 mg/l at 37°C) [24], which 
optimizes its incorporation in the oily core of this nanosystem.
In summary, according to the presented results, the method was 
considered selective, linear for the proposed application range, precise, 
accurate, and robust; therefore, it is properly validated. In addition, 
it was successfully used for quantifying the ISR nanoencapsulated in 
polymeric nanocapsules, providing reliable results.
CONCLUSION
The RP-UHPLC-PDA analytical method proposed above showed to 
be selective, linear, precise, accurate, and robust at the tested range. 
It is suitable for determining ISR loaded in PCL/PEG nanocapsules. 
The obtained nanoformulation presented high loading efficiency. 
These results provided an experimental basis to use this method for 
quantifying ISR from polymeric nanosystems, providing reliable results, 
besides being fast, easy to perform, and cheaper.
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